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Punctate palmoplantar keratodermas (PPKPs) are rare autosomal-dominant inherited skin diseases that are characterized by multiple
hyperkeratotic plaques distributed on the palms and soles. To date, two different loci in chromosomal regions 15q22-15q24 and
8q24.13-8q24.21 have been reported. Pathogenic mutations, however, have yet to be identified. In order to elucidate the genetic cause
of PPKP type Buschke-Fischer-Brauer (PPKP1), we performed exome sequencing in five affected individuals from three families, and we
identified in chromosomal region 15q22.33-q23 two heterozygous nonsense mutations—c.370C>T (p.Arg124*) and c.481C>T
(p.Arg161*)—in AAGAB in all affected individuals. Using immunoblot analysis, we showed that both mutations result in premature
termination of translation and truncated protein products. Analyses of mRNA of affected individuals revealed that the disease allele
is either not detectable or only detectable at low levels. To assess the consequences of the mutations in skin, we performed immunoflu-
orescence analyses. Notably, the amount of granular staining in the keratinocytes of affected individuals was lower in the cytoplasm but
higher around the nucleus than it was in the keratinocytes of control individuals. AAGAB encodes the alpha-and gamma-adaptin-
binding protein p34 and might play a role in membrane traffic as a chaperone. The identification of mutations, along with the results
from additional studies, defines the genetic basis of PPKP1 and provides evidence that AAGAB plays an important role in skin integrity.Palmoplantar keratodermas (PPKs) are familiar skin
diseases characterized by epidermal hyperkeratosis of the
palms and soles.1,2 Punctate palmoplantar keratoderma
(PPKP) type I (PPKP1 [MIM 148600]), also called keratosis
punctate palmoplantaris type Buschke-Fischer-Brauer, is
a rare hereditary skin disease of the palms and soles and
is characterized by multiple hyperkeratotic papules and
central indentation irregularly distributed on the palms
and soles (other palmoplantar keratoses have mostly
diffuse hyperkeratinization). It was first described in 1910
by Buschke, Fischer,3 and Brauer.4 The inheritance pattern
is mostly autosomal dominant, but simplex cases have also
been described.5 Its incidence has not been extensively
evaluated, but it is estimated as 1.17 per 100,000 individ-
uals in Croatia.6 In mechanically irritated areas, confluent
plaques can be found.5 The interfamilial and intrafamilial
severity of the clinical picture shows broad variation. These
lesions usually start to develop in early adolescence but
also later in life.5 There have been reports in which PPK
was associated with the development of both early- and
late-onset malignancies, as well as squamous cell carci-
nomas.7–9
PPKP has previously been mapped to chromosomal
region 15q22-15q24 for PPKP1 (MIM 148600)10 and region
8q24.13-8q24.21 for PPKP3 (MIM 101850),11 but the
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the critical region on chromosome 15 (Figure 1).12–15
Here, we describe the identification of pathogenic
mutations in AAGAB, which encodes the alpha-and
gamma-adaptin-binding protein p34. In addition, expres-
sion studies support the pathogenic role of AAGAB in the
disease.
We identified three families composed of a total of 38
individuals (14 affected and 24 unaffected) available for
further investigation. The disease seemed to be inherited
in an autosomal-dominantmode. Two families are of Croa-
tian origin, and one family is of German origin. All family
members gave informed consent before participating, and
experiments were performed under the approval of the
institutional review board at the Ludwig Maximilians
University of Munich; this approval also included adher-
ence to the Declaration of Helsinki principles. Blood
samples were taken from all 38 individuals. For establish-
ing the phenotype, the palms and soles of all individuals
participating in this study were clinically assessed. Kera-
toses on the soles were more severe than those on the
palms, especially over pressure points (Figure 2). Histology
by hematoxylin eosin (HE) staining showed a marked
hyperkeratosis with focal parakeratosis and prominent hy-
pergranulosis, which is consistent with PPKP1 (Figure S1B,
available online). Phenotypic variability could be observedLudwig Maximilians University, 80337 Munich, Germany; 2Institute of
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Figure 1. Linkage Intervals and Mutation Analysis of AAGAB
(A) In the upper panel, part of chromosome 15 shows the identified linkage intervals and the corresponding flankingmicrosatellites.10–15
The genomic positions of these markers are indicated in Mb. AAGAB resides within the region that was found by Martinez-Mir et al.
(2003)10 and Bchetnia et al. (2009).13 In the lower panel is the genomic structure of AAGAB; ten exons are indicated as black bars.
The noncoding parts of exons 1 and 10 are indicated with smaller bars.
(B) In the left panel is the c.481C>T transition in exon 5 from individual 60698 (pedigree B) and individual 61926 (pedigree C). In the
right panel is the c.370C>T transition in exon 4 from individual 54187 (pedigree A).between, as well as within, families. To identify the genetic
cause of PPKP1, we used exome-sequencing technology.
We selected three cousins (54213, 54187, and 62727)
from pedigree A and two index persons from pedigrees B
(60698) and C (61926) for sequencing under the assump-
tion that any gene harboring rare variants in all members
of the three pedigrees might be a candidate for PPKP1. To
minimize the proportion of alleles shared by descent, we
selected distantly related members of pedigree A.
Sequencing was performed as 100 bp paired-end runs on
HiSeq2000 systems after in-solution enrichment of exonic
sequences (SureSelect XT Human All Exon 50 Mb kit,
Agilent). Read alignment was performed with the
Burrows-Wheeler Aligner (v.0.5.8), and SAMtools (v.0.1.7)
was used for detecting single-nucleotide variants and small
insertions and deletions. We produced an average of 10.5
Gb of mappable sequence per sample, resulting in
a mean read depth of 112, and greater than 88% of the
target regions were covered at least 20 times. Variants
were filtered for excluding those present in dbSNP132
and with an average heterozygosity greater than 0.02 and
those present in more than 4 of 1,400 control exomes
from individuals with other unrelated diseases.
This approach left only a single gene, AAGAB, which
harbors a heterozygous nonsynonymous variant in all
five affected individuals. The three investigated members
of pedigree A showed at nucleotide position 370 a cyto-
sine-to-thymine transition (c.370C>T) leading to a stop
codon at amino acid position 124 (p.Arg124*). In both
pedigrees B and C, we identified at nucleotide position
481 a different nonsense mutation (c.481C>T) alsoThe Americleading to a stop codon at amino acid position 161
(p.Arg161*) (Figure 1).
The variants were confirmed by Sanger sequencing and
analyzed for cosegregation with the phenotype in all three
pedigrees. Primer sequences and conditions for amplifica-
tion for each variant are available upon request. All
affected family members were found to show the muta-
tion, whereas none of the unaffected individuals showed
the mutation (Figure 3). We therefore concluded that the
variants in AAGAB were indeed very likely to be causative
for PPKP1 in pedigrees A, B, and C.
To determine whether variant c.481C>T, which was
present in the affected members of pedigrees B and C,
occurred on the same haplotype, we genotyped 21 individ-
uals from both pedigrees by using oligonucleotide SNP
arrays (HumanOmni2.5-Quad, Illumina). Haplotyping
was performed with Merlin software.16 The haplotypes
showing the c.481C>T variant are depicted in Table S1.
The pedigrees shared a common haplotype across 1.2 Mb
between markers SNP15-67469128 and SNP15-68728632.
The fact that families B and C are of Croatian origin indi-
cates that the affected individuals of family B and family
C inherited the mutation by descent from a common
ancestor.
AAGAB consists of ten exons with a coding sequence of
945 nucleotides. AAGAB has been described to be ubiqui-
tously expressed by array analysis. We specifically showed
by RT-PCR its expression in skin and an immortalized
keratinocyte cell line (HaCaT cells), which is affected in
PPKP1, supporting a role for AAGAB in the pathogenesis
of PPKP1 (Figure S2).an Journal of Human Genetics 91, 754–759, October 5, 2012 755
Figure 2. Clinical Picture
Disseminated hyperkeratotic papules on
palms (A) and soles (B) of a 57-year-old
index person of pedigree B.Alpha-and gamma-adaptin-binding protein p34, whose
subunit interacts with alpha and gamma adaptins might
play a role in membrane trafficking. This interaction was
mapped to these adaptins’ NH2-terminal domains, where
the alpha and gamma adaptins show their highest
homology; however, they are only 32% identical even at
these domains. Another clue to the function of p34 comes
from the observation that it can be coimmunoprecipitated
with soluble adaptor complexes, both AP-1 and AP-2,
although it is not enriched in purified clathrin-coated vesi-
cles. This suggests that p34 might play a chaperone or
chaperone-like role. Thus, it could act to prevent adaptors
from coassembling with soluble clathrin or to participate
in uncoating processes by supporting the removal of adap-
tors from the coated vesicles. p34 might also aid the
recruitment of soluble adaptors onto the membrane.
However, it is unlikely to be involved in the specificity of
adaptor recruitment because it appears to interact equally
well with both adaptor complexes.17
To assess the consequences of the mutations identified
in AAGAB in the skin, we performed immunofluores-
cence analyses on the skin of affected and unaffected
individuals, immunoblotting, and allele-specific PCR
amplification.
For immunofluorescence analyses, normal human skin
from the sole of the foot from four volunteers was used
as a control. Biopsies of affected and unaffected areas of
palm and sole skin were obtained from three affected indi-
viduals (54187, 60698, and 61926) from pedigrees A, B,
and C. All was done with institutional approval and adher-
ence to the Declaration of Helsinki from the Department of
Dermatology at Ludwig Maximilians University Munich
and Medical Faculty of the University of Heidelberg.
Immediately after excision, tissues were snap frozen in
liquid nitrogen and stored at 70C.18
For immunofluorescence staining of AAGAB in normal
and affected skin, we used three polyclonal antibodies
raised against peptides of the unique AAGAB amino acid
sequence composed of positions 126–214 (NBP1-87906),
224–300 (NBP1-87905), and the total recombinant protein
(B01P) (Supplemental Data). In principle, all antisera756 The American Journal of Human Genetics 91, 754–759, October 5, 2012showed staining patterns comparable
to those from mice (B01P; used for
all experiments) that give the stron-
gest labeling (data shown).
In the normal palmoplantar skin
used as a control, AAGAB showed
granular staining in the cytoplasm,
particularly of the stratum basale
and the first suprabasal cell layers
of the stratum spinosum. In upperlayers of the stratum spinosum, cytoplasmic staining is
increasingly lost and only detectable around a few
keratinocyte nuclei (Figure S3A). Regularly, dermal vessels
(‘‘v’’ in Figures S3A–S3C) are also AAGAB-positive in all
specimens.
From the affected persons, we investigated palm and sole
sections of both affected (Figures S3B–S3B00) and unaffected
(Figure S3C) skin areas. In affected regions, the cytoplasmic
labeling was widely reduced and only rarely seen in the
keratinocytes of the stratum basale and the lowermost
stratum spinosum. The granular staining of nuclei was
strongly enhanced and seen in the lower andmiddle layers
of the stratum spinosum (Figures S3B–S3B00). This granular
staining was clearly perinuclear and was best seen at higher
magnifications (Figures S3B0–S3B00). Cytoplasmic and
perinuclear granular staining have been observed previ-
ously.18–22 In these cases, such staining patterns were
caused by keratin clumping of mutated and consequently
defected keratin molecules.
The staining patterns of unaffected areas of affected
persons (Figure S3C) were not significantly different than
those of affected areas (Figure S3B), although the histology
of these areas shows considerably lower stratification and
cornification (Figure S1C). The fact that not all of the
skin of the palms and soles is affected, although the
mutated protein occurs in every cell, is not surprising
because these observations have also been seen in other
genetic skin diseases, such as focal ichthyoses or hyperker-
atoses caused by keratin mutations.23–25
To further assess the consequences of the mutations, we
performed immunoblot analyses. The nonsense mutations
(c.370C>T and c.481C>T) identified in the three families
are predicted to result in premature termination codons
and truncated proteins. To examine both the wild-type
and the truncated AAGAB, we cloned Taq polymerase-
amplified PCR products in a eukaryotic expression vector
by using the pcDNA3.1/V5-His TOPO TA Expression Kit
(Invitrogen, Paisley, UK). The sequences of the primers
used for cloning and sequencing of the respective
constructs are available upon request. The protocols used
for the cloning, cell culture, and immunoblot analysis
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Figure 3. Pedigrees of Families A, B, and C
Pedigrees of families A (A), B (B), and C (C). Unaffected and affected family members are indicated by clear symbols and blackened
symbols, respectively. Asterisks denote individuals genotyped for the variants in AAGAB. To maintain confidentiality, we have not
shown genotypes of unaffected individuals. Diagonal bars through the symbols denote deceased individuals. Question marks in the
symbols denote lacking information about the phenotype.have been described previously.26 COS7 cells were tran-
siently transfected with AAGAB constructs, and cell lysates
were obtained 30 hr after transfection. Protein blots
(Figure 4A) stained with a monoclonal V5 antibody (Invi-
trogen, Paisley, UK) showed a signal of around 40 kDa
(34 kDa without the tag), which corresponds to the size
anticipated for the tagged wild-type protein. The tagged
truncated proteins showed bands in their predicted size
ranges of around 18 and 24 kDa (13.5 and 18 kDa, respec-
tively, without the tag). The strong band for p.Arg161*The Americindicates that the protein is stable and not degraded
(Figure 4A). The faint band for p.Arg124* might indicate
that the corresponding mRNA is mostly prone to mRNA
decay (Figure 4A).
Because the immunoblot analysis is an overexpression
assay and does not necessarily mirror the in vivo situation
in affected individuals, we performed allele-specific PCR
amplification of cDNA of affected individuals (Figure 4B)
and obtained an mRNA transcript amount comparable to
that in protein analyses.an Journal of Human Genetics 91, 754–759, October 5, 2012 757
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Figure 4. Immunoblot and Immuofluorescence Analysis of
COS7 Cells Transiently ExpressingWild-Type and Mutant AAGAB
and Allele-Specific PCR
(A) COS7 cells were transiently transfected with V5-tagged AAGAB
wild-type or mutant (p.Arg124* or p.Arg161*) constructs with the
use of Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions and were harvested 30 hr after transfection.
After lysis of cells in ripa buffer and sonication, lysates were sub-
jected to electrophoresis and immunoblotting. We used mono-
clonalV5 antibody (R960-25, Invitrogen, 1:4.000) todetectAAGAB
proteins. For normalization, we used a monoclonal GAPDH anti-
body (G8795, Sigma-Aldrich, 1:16.000). The wild-type AAGAB
has a size of around 35 kDa, whereas the two truncated proteins
have the anticipated sizes of 14 kDa and 18 kDa. However, we
observe slightly larger bands, which might be due to the added
tag and to glycosylation or phosphorylation of the protein.
(B) Allele-specific PCR was performed with cDNA that was gener-
ated from RNA extracted from the blood of affected individuals.
We used the same forward primer (50-ATGATGCTGTGAGATTTTA
TCCC-30) for all reactions. The reverse primers used for studying
AAGAB expression in individual 54187 were 50-CACCATTCTTGA
GCTTTTTGGCG-30 for amplifying the wild-type allele and 50-
CACCATTCTTGAGCTTTTTGGCA-30 for amplifying the mutant
c.370C>T allele. The reverse primers used for studying AAGAB
expression in individual 60698 were 50- CATTCAGGGCTTGGACA
ATGCG-30 for amplifying the wild-type allele and 50-CATTCAG
GGCTTGGACAATGCA-30 for amplifying the c.481C>T mutant
allele. We readily observed the wild-type allele in both cases,
whereas the mutant allele was only present at reduced levels.
(C) Sequencing results of cDNA samples of affected individuals
with gene-specific AAGAB primers. We could only detect a very
small peak for the c.481C>T allele (arrow on the right), and we
could not detect the c.370C>Tallele at all (arrow on the left), indi-
cating no presence of the respective mutant transcripts.
(D) Immunofluorescence analysis of transiently transfected
HaCaT cells with the above-mentioned V5 antibody. No differ-
ences in staining were observed between cells expressing the
wild-type (left) or the mutant (center ¼ mutant p.Arg124*; and
right ¼ mutant p.Arg161*) AAGAB.
758 The American Journal of Human Genetics 91, 754–759, OctoberTo further test the possibility of mRNA decay, we also
sequenced the respective cDNA samples of affected indi-
viduals (54187 and 60698) with gene-specific AAGAB
primers. We could only detect a very small peak for the
c.481C>T allele, whereas the allele showing the
c.370C>T mutation was undetectable, indicating no pres-
ence of the respective mutant transcripts and thus the loss
of the respective proteins (Figure 4C).
We then performed immunofluorescence analyses to
determine the subcellular localization of the AAGAB
proteins. Human embryonic kidney (HEK) 293 or HaCaT
cells (an immortal human keratinocyte cell line) were
transiently transfected with AAGAB wild-type or mutant
constructs with the use of Lipofectamine 2000 (Invitrogen,
Paisley, UK). Cells were fixed in ice-cold methanol acetone
1:1 for 5 min and then subjected to immunostaining
with a V5 antibody. No differences in staining were
observed between cells expressing the wild-type or the
mutant AAGAB. Both proteins showed a normal distribu-
tion pattern in the cytoplasm (Figure 4D). However, a
strong difference in the transfection efficiency between
wild-type and mutants was obvious.
In summary, we identified two heterozygous nonsense
mutations—c.370C>T (p.Arg124*) and c.481C>T
(p.Arg161*)—in AAGAB. Analysis of mRNA of affected
individuals revealed that the disease allele is either not
detectable or only detectable at low levels, suggesting hap-
loinsufficiency as a possible disease-causing mechanism.
Interestingly, the granular staining that was observed in
the cytoplasm in the skin of control individuals was
widely reduced in the skin of affected individuals. AAGAB
encodes the alpha-and gamma-adaptin-binding protein
p34 and might play a role in membrane trafficking as
a chaperone. Our findings define the genetic basis of
PPKP and provide evidence that AAGAB has an important
role in skin integrity.
AAGAB, whose function was nearly completely
unknown, has thus been identified in processes of the
skin, and its role as a putative chaperone has to be studied
in the future.Supplemental Data
Supplemental Data include Supplemental Material and Methods,
one figure, and one table and can be found with this article online
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